Onofrio Laselva

List of Publications by Year in Descending Order

39 papers	564 citations	14 h-index	23 g-index
47 ext. papers	809 ext. citations	5.8 avg, IF	4.39 L-index

#	Paper	IF	Citations
39	Stage-Specific Generation of Human Pluripotent Stem Cell Derived Lung Models to Measure CFTR Function.. *Current Protocols*, **2022**, 2, e341		0
38	Induced pluripotent stem cells for cystic fibrosis **2022**, 303-332		
37	CFTR interactome mapping using the mammalian membrane two-hybrid high-throughput screening system.. *Molecular Systems Biology*, **2022**, 18, e10629	12.2	2
36	A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein.. *STAR Protocols*, **2022**, 3, 101258	1.4	0
35	Human Amniotic Mesenchymal Stem Cells and Fibroblasts Accelerate Wound Repair of Cystic Fibrosis Epithelium. *Life*, **2022**, 12, 756	3	0
34	Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. *European Respiratory Journal*, **2021**, 57,	13.6	39
33	Small-molecule drugs for cystic fibrosis: Where are we now?. *Pulmonary Pharmacology and Therapeutics*, **2021**, 72, 102098	3.5	1
32	Generation of functional ciliated cholangiocytes from human pluripotent stem cells. *Nature Communications*, **2021**, 12, 6504	17.4	3
31	Three-Dimensional Airway Spheroids and Organoids for Cystic Fibrosis Research. *Journal of Respiration*, **2021**, 1, 229-247	0	2
30	A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients. *Stem Cell Reports*, **2021**, 16, 2825-2837	8	5
29	Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTA. *Journal of Personalized Medicine*, **2021**, 11,	3.6	6
28	Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator. *IScience*, **2021**, 24, 102542	6.1	4
27	Photochemically Activated Notch Signaling Hydrogel Preferentially Differentiates Human Derived Hepatoblasts to Cholangiocytes. *Advanced Functional Materials*, **2021**, 31, 2006116	15.6	5
26	Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants. *Journal of Cystic Fibrosis*, **2021**, 20, 106-119	4.1	21
25	One-Step Formation of Protein-Based Tubular Structures for Functional Devices and Tissues. *Advanced Healthcare Materials*, **2021**, 10, e2001746	10.1	2
24	Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells. *Cells*, **2021**, 10,	7.9	3
23	Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.. *Journal of Cystic Fibrosis*, **2021**,	4.1	5

22	The era of CFTR modulators: improvements made and remaining challenges. *Breathe*, **2020**, 16, 200016	1.8	10
21	The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can Be Rescued by Ivacaftor. *Journal of Personalized Medicine*, **2020**, 10,	3.6	10
20	Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 1118-1128	6.4	19
19	A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations. *European Respiratory Journal*, **2020**, 56,	13.6	12
18	Anti-Infectives Restore ORKAMBI Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of. *Biomolecules*, **2020**, 10,	5.9	21
17	Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action. *Journal of Cystic Fibrosis*, **2020**, 19, 717-727	4.1	37
16	Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators. *Journal of Personalized Medicine*, **2020**, 10,	3.6	12
15	The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. *Expert Opinion on Drug Discovery*, **2020**, 15, 873-891	6.2	13
14	WS13-6 Adenoviral vector gene therapy results in a wild type CFTR functional pattern in class I mutation cystic fibrosis cells. *Journal of Cystic Fibrosis*, **2019**, 18, S25	4.1	4
13	Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). *Cells*, **2019**, 8,	7.9	17
12	ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. *Molecular Pharmacology*, **2019**, 96, 515-525	4.3	31
11	Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis-causing mutation. *FASEB BioAdvances*, **2019**, 1, 661-670	2.8	11
10	Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains. *Molecular Pharmacology*, **2018**, 93, 612-618	4.3	33
9	Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site. *Proteins: Structure, Function and Bioinformatics*, **2018**, 86, 833-843	4.2	31
8	Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators. *Frontiers in Pharmacology*, **2018**, 9, 719	5.6	22
7	Cover Image, Volume 86, Issue 8. *Proteins: Structure, Function and Bioinformatics*, **2018**, 86, C1-C1	4.2	
6	Orkambi and amplifier co-therapy improves function from a rare mutation in gene-edited cells and patient tissue. *EMBO Molecular Medicine*, **2017**, 9, 1224-1243	12	76
5	Correctors of mutant CFTR enhance subcortical cAMP-PKA signaling through modulating ezrin phosphorylation and cytoskeleton organization. *Journal of Cell Science*, **2016**, 129, 1128-40	5.3	30

4	The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain. *Biochemical Pharmacology*, **2016**, 119, 85-92	6	27
3	Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2014**, 307, L48-61	5.8	40
2	Modeling lung cell development using human pluripotent stem cells		3
1	High-throughput functional analysis of CFTR and other apically localized channels in iPSC derived intestinal organoids		2